Bob look where this guy did his residency training AND his past at XOMA. BTW, I just saw George setting up the Lemonade stand in front of the Wohankateer clubhouse. He was mumbling something about a long hot summer.>>>>>>>>>>>Corgentech Announces Appointment of Todd J. Lorenz, M.D., as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire/ -- Corgentech, Inc., a privately-held biotechnology company, announced today that Todd J. Lorenz, M.D., has been appointed Chief Medical Officer. Dr. Lorenz joins Corgentech from Cor Therapeutics, Inc., where he served as its Vice President of Medical Affairs.
Dr. Lorenz will be responsible for all of Corgentech's clinical development activities, focusing primarily on its lead product, the E2F Decoy, a combination drug and device designed to prevent vein grafts used in coronary and peripheral bypass procedures from occluding and failing. The U.S. Food and Drug Administration (FDA) granted "fast track" designation for the E2F Decoy in March.
"Dr. Lorenz's has a breadth of experience developing products, specifically those designed to treat arterial occlusion," said John P. McLaughlin, Corgentech's President and Chief Executive Officer. "He will be enormously helpful as we move the E2F Decoy program into Phase III trials and other research candidates into clinical development."
Previously, Dr. Lorenz served as Vice President of Medical Affairs at Cor Therapeutics where he managed clinical development activities and was focused primarily on the development and regulatory review of the company's first product, INTEGRILIN(TM), which was approved for marketing by the FDA in May 1998 for acute coronary syndromes.
Prior to his tenure at Cor, he served as Director of Clinical Development at Xoma Corporation. Before that, he was in private practice, and also served as a clinical consultant for Highland General Hospital's Department of Endocrinology in Oakland, Calif.
Dr. Lorenz has authored numerous abstracts and publications that have appeared in such prestigious journals as the 'American Journal of Cardiology', 'Journal of the American College of Cardiology', 'Circulation', 'Journal of the Society of Thoracic Surgery', 'The Lancet' and 'The New England Journal of Medicine'.
He received his medical degree from Case Western Reserve University and completed his residency in internal medicine at The University of Texas, Southwestern. He also completed a fellowship in endocrinology at the University of California, San Francisco.
About Corgentech Inc.
Corgentech, Inc., is a privately-held biotechnology company committed to the discovery, development and commercialization of novel molecular- and genetic-based therapies for the treatment of cardiovascular and other serious diseases. The Company's lead product, the E2F Decoy, is designed to prevent vein grafts used in coronary artery and peripheral arterial bypass procedures from blocking and failing and is in the advanced stages of clinical development. Leveraging its leadership in pressure-mediated transfection of decoy oligonucleotides to regulate transactivation of genes, Corgentech's research engine is focused on other promising therapeutic targets to provide treatments for other serious unmet medical needs. For more information on the company and its technology, visit www.corgentech.com.<<<<<<<<<<<<<<<<<< |
